149 related articles for article (PubMed ID: 36823182)
1. Rhamnazin Enhanced Anti-Tumor Efficacy of Anti-PD-1 Therapy for Lung Cancer in Mice through Inhibition of PD-L1 Expression.
Wang SS; Liu Y; Zhang XT; Yu DQ
Tohoku J Exp Med; 2023 May; 260(1):63-73. PubMed ID: 36823182
[TBL] [Abstract][Full Text] [Related]
2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
3. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
5. Evodiamine suppresses non-small cell lung cancer by elevating CD8
Jiang ZB; Huang JM; Xie YJ; Zhang YZ; Chang C; Lai HL; Wang W; Yao XJ; Fan XX; Wu QB; Xie C; Wang MF; Leung EL
J Exp Clin Cancer Res; 2020 Nov; 39(1):249. PubMed ID: 33208183
[TBL] [Abstract][Full Text] [Related]
6. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
[TBL] [Abstract][Full Text] [Related]
7. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
[TBL] [Abstract][Full Text] [Related]
8. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
[TBL] [Abstract][Full Text] [Related]
9. [Effects of anti-PD-L1 monoclonal antibody and EGFR-TKI on the expression of PD-L1 and function of T lymphocytes in EGFR-mutated lung cancer cells].
She Y; Pan X; Xing YF; Zhou T; Zhang ZL; Shi MH; Chen YJ
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):886-892. PubMed ID: 27998463
[No Abstract] [Full Text] [Related]
10. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
Xie C; Zhou X; Liang C; Li X; Ge M; Chen Y; Yin J; Zhu J; Zhong C
J Exp Clin Cancer Res; 2021 Aug; 40(1):266. PubMed ID: 34429133
[TBL] [Abstract][Full Text] [Related]
11. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.
Yuan LW; Jiang XM; Xu YL; Huang MY; Chen YC; Yu WB; Su MX; Ye ZH; Chen X; Wang Y; Lu JJ
Phytomedicine; 2021 Jan; 80():153394. PubMed ID: 33130472
[TBL] [Abstract][Full Text] [Related]
12. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
13. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.
Kim DH; Kim H; Choi YJ; Kim SY; Lee JE; Sung KJ; Sung YH; Pack CG; Jung MK; Han B; Kim K; Kim WS; Nam SJ; Choi CM; Yun M; Lee JC; Rho JK
Exp Mol Med; 2019 Aug; 51(8):1-13. PubMed ID: 31399559
[TBL] [Abstract][Full Text] [Related]
14. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
[TBL] [Abstract][Full Text] [Related]
15. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
16. [Effect of cisplatin alone or combined with monoclonal anti-programmed death ligand-1 antibody on lung adenocarcinoma cell line SPCA-1 and T lymphocytes].
Pan X; Xing Y; Shi M; Zhou T; Qian B; Chen Y
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jun; 37(6):416-20. PubMed ID: 25200040
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
[TBL] [Abstract][Full Text] [Related]
18. Irradiation Suppresses IFNγ-Mediated PD-L1 and MCL1 Expression in EGFR-Positive Lung Cancer to Augment CD8
Wang CI; Chang YF; Sie ZL; Ho AS; Chang JS; Peng CL; Cheng CC
Cells; 2021 Sep; 10(10):. PubMed ID: 34685495
[TBL] [Abstract][Full Text] [Related]
19. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L
Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506
[TBL] [Abstract][Full Text] [Related]
20. TNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy.
De Ridder K; Locy H; Piccioni E; Zuazo MI; Awad RM; Verhulst S; Van Bulck M; De Vlaeminck Y; Lecocq Q; Reijmen E; De Mey W; De Beck L; Ertveldt T; Pintelon I; Timmermans JP; Escors D; Keyaerts M; Breckpot K; Goyvaerts C
Front Immunol; 2022; 13():811867. PubMed ID: 35493461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]